CoreshJ., AstorB.C., GreeneT.. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey.Am J Kidney Dis2003; 41: 1–12.
2.
GansevoortR.T.B., van der HeijB., StegemanC.A.. Trends in the incidence of treated end-stage renal failure in the Netherlands: Hope for the future?Kidney Int2004; 92(suppl): S7–10.
3.
UhligK., MacleodA., CraigJ.. Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO).Kidney Int2006; 70: 2058–65.
4.
El NahasM.E.The global challenge of chronic kidney disease (Nephrology Forum).Kidney Int2005; 68: 2918–29.
5.
HallanS.I., CoreshJ., AstorB.C.. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk.J Am Soc Nephrol2006; 17: 2275–84.
6.
GoA.S., ChertowG.M., FanD., McCullochC.E., HsuC.Y.Chronic kidney disease and the risks of death, cardiovascular events, and hospitalisation.New Engl J Med2004; 351: 1296–305.
7.
WeinerD.E., TabatabaiS., TighiouartH.. Cardiovascular outcomes and all-cause mortality: Exploring the interaction between CKD and cardiovascular disease.Am J Kidney Dis2006; 48: 392–401.
8.
KeithD., NichollsG., GuillionC.. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organisation.Arch Intern Med2004; 164: 659–63.
9.
MannJ.F.E., GersteinH.C., PogueJ.. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial.Ann Intern Med2006; 134: 629–36.
10.
SolomonS.D., RiceM.M., JablonskiK.A.. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the prevention of events with ACE inhibition (PEACE) trial.Circulation2006; 114: 26–3.
11.
AsselbergsF.W., DiercksG.F., HillegeH.L.. Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria.Circulation.2004; 110: 2809–16.
12.
IbsenH., WachtellK., OlsenM.H.. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: The LIFE Study.Kidney Int2004; 66: S56–8.
13.
YuyunM.F., AdlerA.I., WarehamN.J.What is the evidence that microalbuminuria is a predictor of cardiovascular disease events?Curr Opin Nephrol Hypertens2006; 14: 271–6.
14.
World Health Organization.Preventing chronic diseases. A vital investment. World Health Organization, Geneva, Switzerland, 2005.
15.
CodreanuI., PericoN., SharmaS.K., SchieppatiA., RemuzziG.Prevention programmes of progressive renal disease in developing nations.Nephrology2006; 11: 321–8.
16.
PericoN., PlataR., AnabayaA.. Strategies for national health care systems in emerging countries: The case of screening and prevention of renal disease progression in Bolivia.Kidney Int2005; 97(suppl): S87–94.
17.
ManiM.K.Nephrologists sans frontières: Preventing chronic kidney disease on a shoestring.Kidney Int2006; 70: 821–3.
18.
AtthobariJ., AsselbergsF.W., BoersmaC.. Cost-effectiveness of screening for albuminuria with subsequent fosinopril treatment to prevent cardiovascular events: A pharmacoeconomic analysis linked to the PREVEND and PREVENDIT study.Clin Ther2006; 28: 432–44.
19.
LeveyA.S., AndreoliS.P., DuBoseT., ProvenzanoR., CollinsA.J.Chronic kidney disease: Common, harmful and treatable -World Kidney Day 2007.J Am Soc Nephrol (in press, February, 2007).
